← Back to Search

Anti-metabolites

Treatment arm for Arterial Restenosis

N/A
Waitlist Available
Led By Kong Teng Tan, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months post index procedure
Awards & highlights

Study Summary

The purpose of the study is to evaluate the safety and efficacy on the use of drug eluting balloon (DEB) with paclitaxel to treat in-stent restenosis in femoropopliteal arteries.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months post index procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months post index procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Target lesion patency at 6-month follow-up.
Secondary outcome measures
Clinical success up to 12 months post index procedure

Trial Design

1Treatment groups
Active Control
Group I: Treatment armActive Control1 Intervention
SFA angioplasty with In.Pact Admiral drug eluting balloon

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,472 Previous Clinical Trials
484,963 Total Patients Enrolled
Kong Teng Tan, MDPrincipal InvestigatorUniversity Health Network, Toronto
3 Previous Clinical Trials
50 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby Apr 2025